Journal article
Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial
MA Dimopoulos, I Špička, H Quach, A Oriol, R Hájek, M Garg, M Beksac, S Bringhen, E Katodritou, WJ Chng, X Leleu, S Iida, MV Mateos, G Morgan, A Vorog, R Labotka, B Wang, A Palumbo, S Lonial
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2020
DOI: 10.1200/JCO.20.02060
Open access
Abstract
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other options that complement the induction regimen with favorable toxicity are needed. PATIENTS AND METHODS The phase III, double-blind, placebo-controlled TOURMALINE-MM4 study randomly assigned (3:2) patients with NDMM not undergoing ASCT who achieved better than or equal to partial response after 6-12 months of standard induction therapy to receive the oral proteasome inhibitor (PI) ixazomib or placebo on days 1, 8, and 15 of 28-day cycles as mainte..
View full abstractGrants
Funding Acknowledgements
Sponsored by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.